Integrated, intelligent, and fully customizable solutions to enhance diagnostic potential—for every patient and clinical environment
Read highlights from 2022 AACC in Chicago.
We pioneer breakthroughs in healthcare. For everyone. Everywhere.
Join Siemens Healthineers at upcoming conferences and trade shows for laboratory diagnostics.
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
In the U.S., the ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events. The test is not for use in the diagnosis of NASH or for the staging of fibrosis.